2018
Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
Sacks‐Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era. Journal Of The International AIDS Society 2018, 21: e25051. PMID: 29633559, PMCID: PMC5978682, DOI: 10.1002/jia2.25051.Peer-Reviewed Original ResearchConceptsCo-infected populationHIV co-infected populationElimination initiativeHCV eliminationHIV/HCV co-infected populationCare dataHCV treatment uptakeSustained virological responseHalf of patientsDAA eraDAA treatmentHCV careSVR ratesVirological responseHCV infectionHCV treatmentHCV RNAImplementation science frameworkTreatment uptakeHigh-income countriesHIVIntervention characteristicsTreatment availabilityDiagnosis rateElimination program
1995
Women Living with Drug Abuse and HIV Disease: Drug Abuse Treatment Access and Secondary Prevention Issues
Weissman G, Melchior L, Huba G, Smereck G, Needle R, McCarthy S, Jones A, Genser S, Cottler L, Booth R, Altice F. Women Living with Drug Abuse and HIV Disease: Drug Abuse Treatment Access and Secondary Prevention Issues. Journal Of Psychoactive Drugs 1995, 27: 401-411. PMID: 8788695, DOI: 10.1080/02791072.1995.10471704.Peer-Reviewed Original ResearchConceptsHIV secondary preventionDrug abuse treatment servicesDrug abuse treatmentSecondary preventionTreatment servicesAbuse treatmentDrug abuseOutpatient drug-free treatmentSecondary prevention issuesDrug-free treatmentDrug abuse treatment systemFirst yearHIV diseaseInjection drugsService utilizationTreatment accessDrug abusersDrug usersTreatment availabilityPositive findingsOutpatient drug abuse treatmentHealth resourcesDrug detoxificationWomenPrevention issues